The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
ONLY
ARTICLE
November 14, 2022
Neratinib (Nerlynx) for Metastatic HER2-Positive Breast Cancer (online only)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Neratinib (Nerlynx) for Metastatic HER2-Positive Breast Cancer (online only)
November 14, 2022 (Issue: 1663)
The oral tyrosine kinase inhibitor neratinib (Nerlynx –
Puma Biotechnology) has been approved by the FDA
for use in combination with capecitabine (Xeloda, and
generics) for treatment of advanced or metastatic
human epidermal growth factor...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.